Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
GERN Stock Chart & Stats
$1.09
<$0.01(0.15%)
At close: 4:00 PM EST
$1.09
<$0.01(0.15%)
Day’s Range― - ―
52-Week Range$1.09 - $4.50
Previous CloseN/A
Volume1.63M
Average Volume (3M)6.90M
Market Cap
$733.72M
Enterprise ValueN/A
Total Cash (Recent Filing)$387.98M
Total Debt (Recent Filing)$121.84M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Mar 12, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding638,017,100
10 Day Avg. Volume6,339,100
30 Day Avg. Volume6,903,248
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)8.16
Price to Sales (P/S)29.70
P/FCF Ratio-10.43
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$3.30Price Target Upside202.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial StrategyThe company is currently increasing its customer-facing sales teams by more than 20%, which is expected to improve outreach and message delivery to higher decile HCPs.
Leadership ChangesThe hiring of new CEO Harout Semerjian, who has extensive commercial leadership experience, is seen as a positive change.
Sales PerformanceRytelo sales of $49M came in above expectations with strong growth in patient demand.
Bears Say
Demand VariabilityRytelo revenues decline slightly in 3Q25 vs 2Q25, showing continued variability in demand.
Reimbursement ChallengesThe biggest barrier to ex-US commercialization is currently reimbursement rates.
Revenue ShortfallRytelo sales of $47M were below both our ($58M) and Street ($53M) estimates.
Geron News
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.09 and its highest was $4.50 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $733.72M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Mar 12, 2026 which is in 126 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Nov 05, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.032 by $0.002.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp does not currently pay dividends.
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -0.03.
How many shares outstanding does Geron Corp have?
Geron Corp has 638,017,100 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.032. Following the earnings report the stock price went down -5.217%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GERN
Geron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.30 (202.75% Upside)
$3.30 (202.75% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 286.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.94%
12-Months-Change
Fundamentals
Return on Equity
-31.09%
Trailing 12-Months
Asset Growth
23.54%
Trailing 12-Months
Company Description
Geron Corp
Geron Corporation (GERN) is a biopharmaceutical company focused on the development of innovative therapies for cancer treatment. The company specializes in telomere biology and is primarily engaged in the research and development of drugs that target telomerase, an enzyme that plays a crucial role in cancer cell immortality. Geron's lead product candidate, imetelstat, is an investigational telomerase inhibitor being studied for its potential to treat hematologic malignancies, particularly myelofibrosis and acute myeloid leukemia.
GERN Company Deck
GERN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with both positive developments in terms of increased prescribing accounts and new patient starts, as well as financial stability. However, there are significant challenges with declining demand, issues with late-line discontinuations, and the need for increased awareness and education on RYTELO's earlier line use.View all GERN earnings summariesGERN Stock 12 Month Forecast
Average Price Target
$3.30
▲(202.75% Upside)
Technical Analysis
Ownership Overview
0.10% Insiders
11.31% Mutual Funds
0.10% Other Institutional Investors
73.88% Public Companies and Individual Investors